|Table of Contents|

Study on difference in anti-cancer effect and mechanism of ethyl haemaotommate on A549 and HepG2 cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 01
Page:
1-11
Research Field:
Publishing date:

Info

Title:
Study on difference in anti-cancer effect and mechanism of ethyl haemaotommate on A549 and HepG2 cells
Author(s):
TENG Song1; HE Xiaoqiong1; LIANG Zhuoxuan1; YAO Qian2; GU Mengying1; YANG Yuntao1; DONG Ruimei1; GUO Juan1
1.School of Public Health,Kunming Medical University,Yunnan Kunming 650500,China;2.Institute of Yunnan Cancer,the Third Affiliated Hospital of Kunming Medical University,Yunnan Kunming 650100,China.
Keywords:
ethyl haematommate; anti-cancer effect; gene expression; anti-cancer mechanism
PACS:
R73-3
DOI:
10.3969/j.issn.1672-4992.2023.01.001
Abstract:
Objective:To investigate the difference in the anti-cancer effect and mechanisms of ethyl haematommate on A549 and HepG2 cells.Methods:Cells were cultured in vitro.Proliferations of A549 and HepG2 cells were measured by MTT assay.The apoptosis was measured by Annexin V/PI.Flow cytometry was used to detect the effect of ethyl haematommate on the cell cycle.Effect of ethyl haematommate on cloning formation was explored by plate clone formation assay.Effect of ethyl haematommate on migration of A549 and HepG2 cells was detected by cell scratch test.mRNA transcriptome sequencing was used to explore the anti-cancer mechanism of ethyl haematommate,and RT-qPCR experiment was used to verify the sequencing results.Results:The results of MTT showed that the inhibition of the proliferation of A549 and HepG2 cells was a significant dose-effect relationship and time-dependent.Ethyl haematommate could inhibit the clonal formation of cancer cells,promote apoptosis,inhibit cancer cells migration,and could make most cancer cells stagnate in G0/G1 phase.It played an anti-lung cancer by regulating BRCA2,IL-7R and F2,and played anti-liver cancer by regulating STAT1,PAX8,PTGS2,LAMA1.Conclusion:Ethyl haematommate might regulate different genes in A549 and HepG2 cells,which led to the presence of differential sensitivity between the two cells.

References:

［1］TORRE LA,BRAY F,SIEGEL RL,et al.Global cancer statistics,2012［J］.CA Cancer J Clin,2015,65(2):87-108.
［2］SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2016［J］.CA Cancer J Clin,2016,66(1):7-30.
［3］BRAY F,FERKAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
［4］JEMAL A,BRAY F,CENTER MM,et al.Global cancer statistics［J］.CA Cancer J Clin,2011,61(2):69-90.
［5］GONCU B,SEVGI E,KIZILARSLAN HANCER C,et al.Differential anti-proliferative and apoptotic effects of lichen species on human prostate carcinoma cells［J］.PLoS One,2020,15(9):e0238303.
［6］LING CQ,FAN J,LIN HS,et al.Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional C hinese and Western medicine［J］.J Integr Med,2018,16(4):236-248.
［7］LIU J,LINH S,HOU W,et al.Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer:A multicenter,prospective,cohort study［J］.Chin J Integr Med,2017,23(10):733-739.
［8］姜重阳,贺小琼,姚乾,等.地衣活性化合物C11H12O5体外抗肿瘤作用［J］.昆明医科大学学报,2017,38(09):7-10. JIANG CY,HE XQ,YAO Q,et al.In vitro anticancer effects of lichen bioactive compound C11H12O5［J］.Journal of Kunming Medical University,2017,38(09):7-10.
［9］SHEEJA K,LAKSHMI S.Nod-like receptor protein 3 inflammasome in head-and-neck cancer［J］.Journal of Research and Therapeutics,2020,16(3):405-409.
［10］LI P,LIN Z,LIU Q,et al.Enhancer RNA SLIT2 inhibits bone metastasis of breast cancer through regulating P38 MAPK/c-Fos signaling pathway［J］.Front Oncol,2021,15(11):743840.
［11］NOURI Y,WEINKOVE R,PERRET R.T-cell intrinsic Toll-like receptor signaling:implications for cancer immunotherapy and CAR T-cells［J］.J Immunother Cancer,2021,9(11):e003065.
［12］FURI I,SIPOS F,GERMANN TM,et al.Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer:clinico-pathogenic aspects［J］.World J Gastroenterol,2013,19(26):4119-4126.
［13］BARATA JT,DURUM SK,SEDDON B,et al.Flip the coin:IL-7 and IL-7R in health and disease［J］.Nat Immunol,2019,20(12):1584-1593.
［14］MACKALL CL,FRY TJ,GRESS RE.Harnessing the biology of IL-7 for therapeutic application［J］.Nat Rev Immunol,2011,11(5):330- 342.
［15］SPORTES C,BABB RR,KRUMLAUF MC,et al.Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy［J］.Clin Cancer Res,2010,16(2):727- 735.
［16］YASUNAGA M.Antibody therapeutics and immunoregulation in cancer and autoimmune disease［J］.Semin Cancer Biol,2020,64:1-12.
［17］ADACHI T,KOBAYASHI T,SUGIHARA E,et al.Hair follicle-derived IL-7 and IL-15 mediate skin-resident memory T cell homeostasis and lymphoma［J］.Nat Med,2015,21(11):1272- 1279.
［18］MING J,ZHU YJ,DING ZY,et al.Interleukin 7 receptor activates PI3K/Akt/mTOR signaling pathway via downregulation of Beclin-1 in lung cancer［J］.Mol Carcinog,2019,58(3):358-365.
［19］梅楠,赵妮,陈旭阳,等.BRCA2通过PI3K/AKT通路上调ATM抑制乳腺癌的增殖、迁移和侵袭［J］.中国实验诊断学,2021,25(05):756-764. MEI N,ZHAO N,CHEN XY,et al.BRCA2 upregulates ATM through the PI3K/AKT pathway to inhibit the proliferation,migration and invasion of breast cancer［J］.Chinese Experimental Diagnostics,2021,25(05):756-764.
［20］YANG L,WANG J,FAN Y,et al.Hsa_circ_0046264 up-regulated BRCA2 to suppress lung cancer through targeting hsa-miR-1245［J］.Respir Res,2018,19(1):115.
［21］ADAMS GN,ROSENFELDT L,FREDERICK M,et al.Colon cancer growth and dissemination relies upon thrombin,stromal PAR-1,and fibrinogen［J］.Cancer Res,2015,75(19):4235- 4243.
［22］SASIDHARAN V,TOOR SM,ALI BR,et al.Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells［J］.Expert Opin Ther Targets,2018,22(6):547-557.
［23］YANG B,YANG E,LIAO H,et al.ARNT2 is downregulated and serves as a potential tumor suppressor gene in non-small cell lung cancer［J］.Tumour Biol,2015,36(3):2111- 2119.
［24］JIANG H,LI H.Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer:a systematic review and meta-analysis［J］.BMC Cancer,2021,21(1):149.
［25］LAM SW,CLEVEN AHG,BRIAIRDE BRUIJN IH,et al.FOS rearrangement and expression in cementoblastoma［J］.Am J Surg Pathol,2021,45(5):690-693.
［26］XU Z,ZHANG Y,XU M,et al.Demethylation and overexpression of CSF2 are involved in immune response,chemotherapy resistance,and poor prognosis in colorectal cancer［J］.Onco Targets Ther,2019,12:11255-11269.
［27］ALDINGER KA,MOSCA SJ,TETREAULT M,et al.Mutations in LAMA1 cause cerebellar dysplasia and cysts with and without retinal dystrophy［J］.Am J Hum Genet,2014,95(2):227- 234.
［28］李娟.PAX8-AS1基因多态性与肺癌易感性的关系［D］.沈阳：中国医科大学,2019. LI J.The association between PAX8-AS1 polymorphism and suspceptibility to lung cancer ［D］.Shenyang:Chinese Medical Sciences University,2019.
［29］KUNZMANN AT,MURRAY LJ,CARDWELL CR,et al.PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients:a systematic review［J］.Cancer Epidemiol Biomarkers Prev,2013,22(9):1490- 1497.
［30］GUTIERREZ-HOYA A,SOTO-CRUZ I.Role of the JAK/STAT pathway in cervical cancer:its relationship with HPV E6/E7 oncoproteins［J］.Cells,2020,9(10):2297.
［31］VON HOFF L,KARGEL E,FRANKE V,et al.Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma［J］.Blood,2019,133(13):1489-1494.
［32］LIU P,LU Z,LIU L,et al.NOD-like receptor signaling in inflammation-associated cancers:From functions to targeted therapies［J］.Phytomedicine,2019,64:152925.

Memo

Memo:
National Natural Science Foundation of China（No.81760538）;国家自然科学基金项目(编号：81760538);云南省高校创新团队建设项目（编号：云教发2019-58）;云南省科技厅项目(编号：U0120170177)
Last Update: 2022-11-30